Illumina Ventures is an independently managed venture capital firm established in 2016 as a strategic subsidiary. See sector focus and contact routes.
Illumina Ventures is an independently managed venture capital firm established in 2016 as a strategic subsidiary of Illumina, Inc., dedicated to advancing genomics and precision health to improve human health. The firm invests exclusively in early-stage life science companies across life science tools, clinical diagnostics, therapeutics, and personal wellness, operating primarily in North America with a global scope. It typically leads investment rounds and co-invests with other institutional partners, with a historical maximum check size of $105 million and a recent $50 million equity investment in Alamar Biosciences. Notable portfolio companies include 23andMe, Twist Bioscience, Sherlock Biosciences, Actym Therapeutics, and Redshift Bio. The firm’s distinctive point of view leverages its strategic relationship with Illumina to access deep genomics expertise, emphasizing backing strong teams with broadly applicable technology platforms targeting large markets. Its mission centers on translating investment into innovation by supporting startups from seed stage through IPO to accelerate impact on human health.
StartupFundraising tracks this firm record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to comparable investors.
Investors like Illumina Ventures · Full investor directory · Investor access · Company funding database